跳至主要内容
临床试验/jRCT1031240320
jRCT1031240320招募中不适用

Exploratory study of biomarkers associated with "Phase III study of gemcitabine, cisplatin plus S-1 combination therapy versus gemcitabine, cisplatin plus immune checkpoint inhibitor combination therapy in advanced biliary tract cancer" (Biomarker study for YOTSUBA trial)

Kanagawa Cancer Center0 个研究点目标入组 170 人开始时间: 2024年8月26日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
170
主要终点
Creation of a multivariate discriminant model

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Biliary tract cancer patients enrolled in "Phase III study of gemcitabine, cisplatin plus S-1 combination therapy versus gemcitabine, cisplatin plus immune checkpoint inhibitor combination therapy in advanced biliary tract cancer" (KHBO-2201)

排除标准

  • History of immunotherapy (anti-PD-1/PD-L1 antibody therapy, anti-CTLA-4 antibody therapy, cancer vaccine therapy, immune cell therapy, etc.).
  • Regular use of amino acid preparations (intravenous nutrition, enteral component nutrition, etc.) or amino acid supplements (concomitant use of anamorelin hydrochloride is acceptable).
  • Presumed abnormalities of amino acid metabolism (cirrhosis, renal failure, congenital abnormalities of amino acid metabolism, etc.).

结局指标

主要结局

Creation of a multivariate discriminant model

Combination of plasma amino acid concentrations to predict overall survival in advanced biliary tract cancer patients treated with gemcitabine/cisplatin/S-1 combination therapy and gemcitabine/cisplatin/immune checkpoint inhibitor combination therapy.

次要结局

  • Creation of a multivariate discriminant model

研究者

相似试验